Market Overview:
The global dolutegravir/rilpivirine combination drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing prevalence of HIV, rising demand for novel antiretroviral therapies, and growing investments in R&D for the development of new drugs. Based on type, the global dolutegravir/rilpivirine combination drug market can be segmented into self-production API and outsourcing of API. The self-production API segment is expected to account for a larger share of the market in 2018 owing to lower production costs as compared to outsourcing APIs. However, with increasing competition among manufacturers, there is an increased focus on outsourcing APIs in order to reduce production costs and improve product quality. Based on application, the global dolutegravir/rilpivirine combination drug market can be divided into hospital pharmacies, retail pharmacies (clinics), drug centers (specialty pharmacies), and other applications (such as research institutes). The hospital pharmacy segment is expected to account for a larger share of the overall market in 2018 due its large customer base and widespread distribution network across hospitals worldwide.
Product Definition:
A once-daily, single pill that contains the antiretroviral drugs dolutegravir and rilpivirine. It is used to treat HIV-1 infection in adults who have never taken HIV medicines before. It is also used to replace a current regimen for people who have been taking other HIV medicines.
Self-production API:
Self-production API, also known as biological production or bioprocessing production, is the process of producing APIs by using living organisms. The most common way to produce APIs is through a fermentation process. Fermentation can be carried out in either a chemical or biological environment. Biological processes are generally performed in microorganisms such as E.
Outsourcing of API:
Outsourcing of API is a practice where pharmaceutical companies contract manufacturers to produce drug products such as APIs (Active Pharmaceutical Ingredients) and finished drug products. The main driver for outsourcing of API is cost-effectiveness, reduced production time, increased efficiency & productivity, access to cutting edge technology and expertise along with compliance with GMP/GMP quality standards. Outsourcing of API also helps in maintaining the intellectual property rights along with protecting confidential information which cannot be included in the product specifications.
Application Insights:
Based on application, the global market is segmented into hospital, clinic, drug center and others. The hospital segment dominated the overall industry in terms of revenue in 2017. This can be attributed to factors such as high prevalence of HIV and increasing number of patients seeking treatment at hospitals due to financial constraints. As a result, companies are focusing on manufacturing their products through outsourcing partnerships with generic manufacturers or by producing the drugs internally which will subsequently lead to an increase in demand over the forecast period.
The other segment that includes pharmacies and private practices accounted for a relatively smaller share as compared to other segments owing to various factors such as competition from large pharmaceutical companies who have their own clinics/prescription offices near their manufacturing facilities or partnership agreements with local governments where they provide free medication services for residents living near these government-owned medical facilities (Drug Center).
Regional Analysis:
North America is expected to be the largest regional market over the forecast period owing to high demand for highly effective, low-cost drugs. The U.S., in particular, is a major revenue contributor in this region due to the presence of key players and well-established healthcare infrastructure. In addition, increasing prevalence of HIV/AIDS and growing awareness about drug therapies are further expected to drive regional growth during the forecast period.
Asia Pacific is anticipated to be one of the fastest growing regions during Dolutegravir/Rilpivirine Combination Drug Market by Type (Self-production API, Outsourcing of API) And by Application And Region Forecast from 2018 To 2030 time as a result of rising number patients suffering from HIV infection and improving access & affordability issues pertaining with these medicines in developing countries such as India & China etc.
Growth Factors:
- Increasing incidence of HIV/AIDS: The global incidence of HIV is on the rise and is expected to reach 36 million by 2020. This will create a large pool of patients who will require treatment, thereby driving the demand for Dolutegravir/Rilpivirine combination drug.
- Rising awareness about HIV and its treatment: There is an increasing awareness among people about HIV and its treatment options. This is likely to drive the demand for Dolutegravir/Rilpivirine combination drug in the coming years.
- Availability of generic versions: The availability of low-cost generic versions of Dolutegravir/Rilpivirine combination drug will help increase its adoption in developing countries.
- Growing number of clinical trials: The number of clinical trials involving Dolutegravir/Rilpivirine combination drug is growing rapidly, which indicates that it has potential to become a mainstream therapy option in the near future .
Scope Of The Report
Report Attributes
Report Details
Report Title
Dolutegravir/Rilpivirine Combination Drug Market Research Report
By Type
Self-production API, Outsourcing of API
By Application
Hospital, Clinic, Drug Center, Other
By Companies
ViiV Healthcare, JNJ
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Dolutegravir/Rilpivirine Combination Drug Market Report Segments:
The global Dolutegravir/Rilpivirine Combination Drug market is segmented on the basis of:
Types
Self-production API, Outsourcing of API
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Drug Center, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ViiV Healthcare
- JNJ
Highlights of The Dolutegravir/Rilpivirine Combination Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Self-production API
- Outsourcing of API
- By Application:
- Hospital
- Clinic
- Drug Center
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dolutegravir/Rilpivirine Combination Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dolutegravir/rilpivirine is a combination drug used to treat HIV. It works by blocking the virus from entering cells and replicating.
Some of the major companies in the dolutegravir/rilpivirine combination drug market are ViiV Healthcare, JNJ.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Dolutegravir/Rilpivirine Combination Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Dolutegravir/Rilpivirine Combination Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Dolutegravir/Rilpivirine Combination Drug Market - Supply Chain
4.5. Global Dolutegravir/Rilpivirine Combination Drug Market Forecast
4.5.1. Dolutegravir/Rilpivirine Combination Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Dolutegravir/Rilpivirine Combination Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Dolutegravir/Rilpivirine Combination Drug Market Absolute $ Opportunity
5. Global Dolutegravir/Rilpivirine Combination Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Type
5.3.1. Self-production API
5.3.2. Outsourcing of API
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Dolutegravir/Rilpivirine Combination Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Drug Center
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Dolutegravir/Rilpivirine Combination Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Dolutegravir/Rilpivirine Combination Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Dolutegravir/Rilpivirine Combination Drug Demand Share Forecast, 2019-2026
9. North America Dolutegravir/Rilpivirine Combination Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Drug Center
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Type
9.7.1. Self-production API
9.7.2. Outsourcing of API
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Dolutegravir/Rilpivirine Combination Drug Demand Share Forecast, 2019-2026
10. Latin America Dolutegravir/Rilpivirine Combination Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Drug Center
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Type
10.7.1. Self-production API
10.7.2. Outsourcing of API
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Dolutegravir/Rilpivirine Combination Drug Demand Share Forecast, 2019-2026
11. Europe Dolutegravir/Rilpivirine Combination Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Drug Center
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Type
11.7.1. Self-production API
11.7.2. Outsourcing of API
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Dolutegravir/Rilpivirine Combination Drug Demand Share, 2019-2026
12. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Drug Center
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Type
12.7.1. Self-production API
12.7.2. Outsourcing of API
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Dolutegravir/Rilpivirine Combination Drug Demand Share, 2019-2026
13. Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Drug Center
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Market Size and Volume Forecast by Type
13.7.1. Self-production API
13.7.2. Outsourcing of API
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Dolutegravir/Rilpivirine Combination Drug Market: Market Share Analysis
14.2. Dolutegravir/Rilpivirine Combination Drug Distributors and Customers
14.3. Dolutegravir/Rilpivirine Combination Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. ViiV Healthcare
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. JNJ
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. COMPANY3
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
